2-ethyl-5-trifluoromethyl-1(3)H-benzoimidazole | 14763-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-ethyl-5-trifluoromethyl-1(3)H-benzoimidazole
• 英文别名: 1H-Benzimidazole, 2-ethyl-6-(trifluoromethyl)-；2-ethyl-6-(trifluoromethyl)-1H-benzimidazole
• CAS: 14763-95-2
• 化学式: C₁₀H₉F₃N₂
• 分子量: 214.19
• InChiKey: DFPKWQXMHIQJHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
  申请人：Dankulich P. William

  公开号：US20070088047A1

  公开（公告）日：2007-04-19

  Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性方式调节雄激素受体（AR）。它们可作为雄激素受体在骨骼和/或肌肉组织中的激动剂，同时在男性患者的前列腺或女性患者的子宫中对抗雄激素受体。因此，这些化合物在增强肌肉张力和治疗由雄激素缺乏引起或可以通过雄激素治疗改善的疾病方面具有用途，包括骨质疏松症、骨质疏松症、糖皮质激素诱导的骨质疏松症、牙周病、骨折、骨重建手术后的骨损伤、肌肉减少症、虚弱、老化皮肤、男性睾丸功能减退、女性绝经后症状、动脉粥样硬化、高胆固醇血症、高脂血症、肥胖、再生障碍性贫血和其他造血系统疾病、炎症性关节炎和关节修复、艾滋病消耗综合征、前列腺癌、癌症消耗综合征、阿尔茨海默病、肌肉萎缩症、认知障碍、性欲减退、卵巢早衰和自身免疫疾病等疾病的治疗，可单独使用或与其他活性药物联合使用。
• HETEROCYCLIC CETP INHIBITORS
  申请人：Wang Yufeng

  公开号：US20070135467A1

  公开（公告）日：2007-06-14

  Compounds of formula Ia and Ib wherein A, B, C and R 1 are described herein.

  本文描述的是化学式Ia和Ib的化合物，其中A、B、C和R1被定义。
• Substituted Purine And 7-Deazapurine Compounds
  申请人：Olhava Edward J.

  公开号：US20120142625A1

  公开（公告）日：2012-06-07

  The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代嘌呤和7-脱氮嘌呤化合物。本发明还涉及包含这些化合物的药物组合物，以及通过向需要这些化合物和药物组合物的受试者施用这些化合物和药物组合物来治疗DOT1介导的蛋白质甲基化参与的疾病，例如癌症和神经系统疾病的方法。
• Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
  申请人：BioElectron Technology Corporation

  公开号：US10189830B2

  公开（公告）日：2019-01-29

  Disclosed herein are alkyl-heteroaryl substituted quinone derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

  本文公开了烷基-杂芳基取代的醌衍生物化合物以及使用此类化合物治疗或抑制氧化应激紊乱（包括线粒体紊乱、能量处理受损紊乱、神经退行性疾病和衰老疾病）的方法。
• ANTIBACTERIAL COMPOUNDS
  申请人：Redx Pharma PLC

  公开号：US20190040083A1

  公开（公告）日：2019-02-07

  This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial infections and in methods of treating bacterial infections.